Advertisement

ADVERTISEMENT

Leukemia & Lymphoma

News
MRD Testing to Identify High-Risk MCL Cases That Could Benefit From Alternate Therapies
12/08/2019
Study findings being presented at ASH 2019 posit that interim MRD testing at cycle 3 can help identify high-risk patients with MCL who may benefit from alternative therapies.
Study findings being presented at ASH 2019 posit that interim MRD testing at cycle 3 can help identify high-risk patients with MCL who may benefit from alternative therapies.
Study findings being presented...
12/08/2019
Oncology
News
Maintenance Decitabine Impacts DFS and OS After Intensive Therapy in Older Adults With AML
12/08/2019
Relapse is the most common cause of treatment failure following intensive induction and consolidation (CONS) therapy in older adults with acute myeloid leukemia (AML).
Relapse is the most common cause of treatment failure following intensive induction and consolidation (CONS) therapy in older adults with acute myeloid leukemia (AML).
Relapse is the most common cause...
12/08/2019
Oncology
News
Researchers Identify Significant Risk Factors for Treatment Response to CD-19 CAR-T Therapy in ALL
12/08/2019
Results from an analysis presented at the 2019 ASH Annual Meeting reveal significant risk factors for worse treatment response after CD-19 CAR T-cell therapy in relapsed/refractory B-ALL.
Results from an analysis presented at the 2019 ASH Annual Meeting reveal significant risk factors for worse treatment response after CD-19 CAR T-cell therapy in relapsed/refractory B-ALL.
Results from an analysis...
12/08/2019
Oncology
News
Vosaroxin and Cytarabine Yield Less Toxicity Than Standard AML Therapy
12/08/2019
Findings presented at ASH 2019 demonstrate that vosaroxin and infusional cytarabine are a safe treatment regimen for newly diagnosed patients with AML.
Findings presented at ASH 2019 demonstrate that vosaroxin and infusional cytarabine are a safe treatment regimen for newly diagnosed patients with AML.
Findings presented at ASH 2019...
12/08/2019
Oncology
News
Acalabrutinib With or Without Obinutuzumab Improved PFS Over Obinutuzumab Plus Chlorambucil in Treatment-Naïve CLL
12/08/2019
Acalabrutinib has demonstrated durable responses as a single agent or combined with obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).
Acalabrutinib has demonstrated durable responses as a single agent or combined with obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).
Acalabrutinib has demonstrated...
12/08/2019
Oncology
Comparing Sequential Monotherapy With Combo Therapy in CLL
10/25/2019
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important...
10/25/2019
Oncology
News
Management of Patients With Relapsed T-Cell ALL
10/23/2019
Pinkal Desai, MD, MPH, discusses the management of difficult cases of ALL, particularly relapsed T-cell disease.
Pinkal Desai, MD, MPH, discusses the management of difficult cases of ALL, particularly relapsed T-cell disease.
Pinkal Desai, MD, MPH, discusses...
10/23/2019
Oncology
Selecting, Switching, and Discontinuing First-Line TKIs in CML
10/23/2019
Dr Lee tells attendees of the Lymphoma & Myeloma Congress about current approaches to optimizing the care of patients with CML in the era of TKIs.
Dr Lee tells attendees of the Lymphoma & Myeloma Congress about current approaches to optimizing the care of patients with CML in the era of TKIs.
Dr Lee tells attendees of the...
10/23/2019
Oncology
News
Increased IV Immunoglobulin Use in Patients With CLL Hospitalized for ITP
06/14/2019
Patients with CLL hospitalized for ITP were more likely to require IV immunoglobulin than steroids as ITP therapy.
Patients with CLL hospitalized for ITP were more likely to require IV immunoglobulin than steroids as ITP therapy.
Patients with CLL hospitalized...
06/14/2019
Oncology
Videos
Brentuximab Vedotin Continues to Demonstrate Superior Clinical Activity in Hodgkin Lymphoma
06/10/2019
David J. Straus, MD, discusses the 3-year follow-up results from the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.
David J. Straus, MD, discusses the 3-year follow-up results from the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.
David J. Straus, MD, discusses...
06/10/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

March 23 ⁠–⁠ March 24
April 27 ⁠–⁠ April 28
Great Debates & Updates in Diabetic Foot
November 30 ⁠–⁠ December 2
November 27 ⁠–⁠ November 29
AIBD logo
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
May 13 ⁠–⁠ May 14
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use